InnoCare Pharma gets green light for Phase II trial of oral lupus drug
CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions
CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions
Provides pain relief for more than 30 conditions, including chronic back pain, arthritis, and sports injuries
Under the 2023 collaboration agreement, Assembly Bio will receive $35 million for Gilead’s exercise of the HSV program option
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress
GSK will make most of its inhaled respiratory portfolio and other products available on a direct purchasing platform, offering savings of up to 66%
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
Subscribe To Our Newsletter & Stay Updated